Brigatinib

Use

Brigatinib is available in 30mg, 90mg, and 180mg tablets. For the treatment of NSCLC for patients who are intolerant to crizotinib or those whose condition has progressed, 90mg should be taken orally 2 times per day for 7 days and if the drug is well-tolerated the dosage indication can be increased to 180 mg PO qDay. A patient should continue treatment with the drug until disease progression or when it results in unacceptable toxicity. For coadministration with other CYP3A inhibitors, the Brigatinib dosage should be reduced by 50%, for example, from 90mg to 60mg. After discontinuation of treatment with potent CYP3A inhibitors, the patient can resume their initial dosage indications for Brigatinib especially if it was well tolerated. Brigatinib can be taken with or without food. If a patient misses their doses for 14, they can resume treatment at 90mg taken as a single daily dose for 7days. The dosage may also increase to previously well-tolerated levels.

Brigatinib manufacturers

• Brigatinib
• 
• US $0.00 / g
• 2024-08-05
• CAS:1197953-54-0
• Min. Order: 1g
• Purity: More Than 99%
• Supply Ability: 100kg/Month

• Brigatinib
• 
• US $0.00-0.00 / kg
• 2024-08-03
• CAS:1197953-54-0
• Min. Order: 1kg
• Purity: 99.0%
• Supply Ability: 10000

• Ap26113;Brigatinib
• 
• US $0.00 / kg
• 2024-05-13
• CAS:1197953-54-0
• Min. Order: 1kg
• Purity: 99%
• Supply Ability: 10000kg